MCID: GLC086
MIFTS: 43

Glucocorticoid-Induced Osteoporosis

Categories: Bone diseases

Aliases & Classifications for Glucocorticoid-Induced Osteoporosis

MalaCards integrated aliases for Glucocorticoid-Induced Osteoporosis:

Name: Glucocorticoid-Induced Osteoporosis 12 15
Steroid-Induced Osteoporosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060343

Summaries for Glucocorticoid-Induced Osteoporosis

Disease Ontology : 12 An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

MalaCards based summary : Glucocorticoid-Induced Osteoporosis, also known as steroid-induced osteoporosis, is related to synovitis and arthropathy. An important gene associated with Glucocorticoid-Induced Osteoporosis is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Wnt signaling pathway and RANK Signaling in Osteoclasts. The drugs Tocopherol and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and bone marrow, and related phenotypes are cellular and growth/size/body region

Wikipedia : 74 Steroid-induced osteoporosis is osteoporosis arising due to use of glucocorticoids (steroid hormones) -... more...

Related Diseases for Glucocorticoid-Induced Osteoporosis

Diseases related to Glucocorticoid-Induced Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 synovitis 30.4 TNFSF11 TNFRSF11B ACP5
2 arthropathy 30.3 TNFSF11 TNFRSF11B IGF1
3 secondary hyperparathyroidism 30.3 VDR TNFRSF11B PTH CALCA BGLAP ACP5
4 rickets 30.2 VDR PTH CD36 CALCA BGLAP
5 hypervitaminosis d 30.2 VDR PTH CALCA
6 connective tissue disease 30.1 TNFSF11 TNFRSF11B RUNX2 PTH CD36 BGLAP
7 osteomyelitis 30.0 TNFSF11 CALCA BMP2 ACP5
8 nephrolithiasis 29.8 VDR TNFRSF11B PTH BGLAP
9 hyperthyroidism 29.8 PTH IGF1 CALCA BGLAP ACP5
10 periodontitis 29.6 VDR TNFSF11 TNFRSF11B RUNX2 BGLAP ACP5
11 arthritis 29.5 TNFSF11 PTH FOS CSF1 ACP5
12 rheumatoid arthritis 29.5 TNFSF11 TNFRSF11B PTH FOS CSF1 BGLAP
13 osteomalacia 29.4 VDR TNFSF11 SOST PTH CALCA BGLAP
14 osteopetrosis 29.4 TNFSF11 TNFRSF11B RUNX2 CSF1 CALCA BGLAP
15 osteonecrosis 29.2 TNFSF11 TNFRSF11B RUNX2 PTH IGF1 DKK1
16 hyperparathyroidism 29.1 VDR TNFSF11 TNFRSF11B SOST PTH IGF1
17 sclerosteosis 28.7 VDR TNFSF11 TNFRSF11B SOST SFRP1 RUNX2
18 primary hyperparathyroidism 28.6 VDR TNFSF11 TNFRSF11B SOST PTH IGF1
19 osteogenic sarcoma 28.4 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
20 bone resorption disease 28.0 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
21 bone disease 27.4 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
22 osteoporosis 26.2 VDR TSC22D3 TNFSF11 TNFRSF11B SOST SFRP1
23 bone mineral density quantitative trait locus 8 11.4
24 bone mineral density quantitative trait locus 15 11.4
25 triiodothyronine receptor auxiliary protein 10.5
26 polyarticular onset juvenile idiopathic arthritis 10.5 TNFSF11 TNFRSF11B
27 hypogonadism 10.4
28 hemophilic arthropathy 10.4 TNFSF11 TNFRSF11B
29 autoimmune disease 10.4
30 periodontitis, chronic 10.4 TNFSF11 TNFRSF11B
31 substernal goiter 10.4 PTH CALCA
32 paget disease of bone 5, juvenile-onset 10.4 TNFSF11 TNFRSF11B CALCA
33 temporal arteritis 10.4
34 malignant ovarian brenner tumor 10.3 TNFSF11 PTH CALCA
35 bone giant cell sarcoma 10.3 TNFSF11 CSF1
36 nontoxic goiter 10.3 PTH CALCA BGLAP
37 multicentric reticulohistiocytosis 10.3 TNFSF11 TNFRSF11B CSF1
38 gorham's disease 10.3 TNFSF11 PTH CALCA
39 giant cell reparative granuloma 10.3 TNFSF11 PTH CALCA
40 differentiated thyroid carcinoma 10.3 TNFRSF11B CD36 BGLAP
41 chondrodysplasia, blomstrand type 10.3 TNFSF11 PTH BGLAP
42 thyroid gland disease 10.3 PTH IGF1 CALCA
43 osteopetrosis, autosomal dominant 2 10.3 TNFSF11 BGLAP ACP5
44 dental pulp necrosis 10.3 TNFSF11 BMP2 BGLAP
45 disseminated chorioretinitis 10.3 TNFSF11 TNFRSF11B
46 goiter 10.3 IGF1 CALCA BGLAP
47 villonodular synovitis 10.3 TNFSF11 CSF1 ACP5
48 craniometaphyseal dysplasia, autosomal dominant 10.3 TNFSF11 RUNX2 BGLAP
49 periapical periodontitis 10.3 TNFSF11 TNFRSF11B ACP5
50 bone mineral density quantitative trait locus 3 10.3

Graphical network of the top 20 diseases related to Glucocorticoid-Induced Osteoporosis:



Diseases related to Glucocorticoid-Induced Osteoporosis

Symptoms & Phenotypes for Glucocorticoid-Induced Osteoporosis

MGI Mouse Phenotypes related to Glucocorticoid-Induced Osteoporosis:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 AXIN2 BGLAP BMP2 CD36 CSF1 DKK1
2 growth/size/body region MP:0005378 10.38 AXIN2 BMP2 CD36 CSF1 DKK1 FOS
3 craniofacial MP:0005382 10.29 AXIN2 BMP2 CSF1 DKK1 FOS PAX5
4 cardiovascular system MP:0005385 10.28 AXIN2 BMP2 CD36 CSF1 IGF1 PAX5
5 hematopoietic system MP:0005397 10.28 BGLAP BMP2 CD36 CSF1 FOS IGF1
6 endocrine/exocrine gland MP:0005379 10.27 AXIN2 BGLAP CD36 CSF1 FOS IGF1
7 homeostasis/metabolism MP:0005376 10.25 BGLAP BMP2 CD36 CSF1 DKK1 FOS
8 immune system MP:0005387 10.21 BGLAP BMP2 CD36 CSF1 FOS IGF1
9 limbs/digits/tail MP:0005371 10.13 AXIN2 BMP2 CSF1 DKK1 FOS IGF1
10 mortality/aging MP:0010768 10.1 AXIN2 BMP2 CD36 CSF1 DKK1 FOS
11 hearing/vestibular/ear MP:0005377 10 BMP2 CSF1 FOS IGF1 PAX5 TNFRSF11B
12 nervous system MP:0003631 9.9 AXIN2 BMP2 CD36 CSF1 DKK1 FOS
13 reproductive system MP:0005389 9.7 AXIN2 BGLAP BMP2 CSF1 FOS IGF1
14 skeleton MP:0005390 9.53 AXIN2 BGLAP BMP2 CD36 CSF1 DKK1

Drugs & Therapeutics for Glucocorticoid-Induced Osteoporosis

Drugs for Glucocorticoid-Induced Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
5
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
6
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
9
Denosumab Approved Phase 4 615258-40-7
10
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
14
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
15 Tocotrienol Investigational Phase 4 6829-55-6
16 Calciferol Phase 4
17 Tocotrienols Phase 4
18 Tocopherols Phase 4
19 Trace Elements Phase 4
20 Vitamins Phase 4
21 Hydroxycholecalciferols Phase 4
22 Nutrients Phase 4
23 Micronutrients Phase 4
24 Hormones Phase 4
25 Calcium, Dietary Phase 4
26 Ibandronic Acid Phase 4
27 Hormone Antagonists Phase 4
28 calcium channel blockers Phase 4
29 glucocorticoids Phase 4
30
Calcium Nutraceutical Phase 4 7440-70-2 271
31
Ferrous fumarate Approved Phase 3 141-01-5
32
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
33
Norethindrone Approved Phase 3 68-22-4 6230
34
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
35
Polyestradiol phosphate Approved Phase 3 28014-46-2
36
Genistein Investigational Phase 2, Phase 3 446-72-0 5280961
37 Protein Kinase Inhibitors Phase 2, Phase 3
38 Phytoestrogens Phase 2, Phase 3
39 Estrogens Phase 3
40 Estradiol 17 beta-cypionate Phase 3
41 Contraceptive Agents Phase 3
42 Contraceptives, Oral Phase 3
43 Contraceptives, Oral, Hormonal Phase 3
44 Estradiol 3-benzoate Phase 3
45 Contraceptives, Oral, Combined Phase 3
46 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 3
47 Norethindrone Acetate Phase 3
48 Norinyl Phase 3
49 Diphosphonates Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
2 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
3 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
4 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
5 Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial Completed NCT03005678 Phase 4 Denosumab;Alendronate
6 HRT and/or Etidronate in the Prevention and Treatment of Osteoporosis and Fractures in Post-Menopausal Patients With Asthma Receiving Long-Term Oral and/or Inhaled Glucocorticoids:a Randomised Factorial Trial Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
7 Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis? Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
8 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
9 Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial Not yet recruiting NCT04091243 Phase 4 Romosozumab
10 Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study Not yet recruiting NCT04177940 Phase 4 DMAB Discontinuation and Switching
11 Randomised, Double Blind, Placebo Controlled Trial to Ascertain the Efficacy and Safety of Intravenous Zoledronic Acid in Adult Patients With Cystic Fibrosis. Withdrawn NCT01702415 Phase 4 Zoledronic acid;Placebo
12 Metabolic, Endocrine, and Central Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis Unknown status NCT03040531 Phase 2, Phase 3 Alendronate Oral Tablet
13 Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis Completed NCT00051558 Phase 3 Teriparatide;Alendronate Sodium;Placebo;Placebo
14 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
15 A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals Completed NCT01575873 Phase 3 Denosumab;Placebo for risendronate;Risendronate;Placebo for denosumab
16 Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men Completed NCT00503399 Phase 3 Teriparatide;Risedronate
17 Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Oral Contraceptives Completed NCT00000420 Phase 3 Ortho-Novum 777
18 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis Recruiting NCT03164928 Phase 3 Denosumab
19 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
20 Can PTH Reverse Glucocorticoid-induced Osteoporosis Completed NCT00004993 Phase 2 Parathyroid hormone (hPTH 1-34)
21 Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women Completed NCT01440803 Phase 2 Teriparatide;Saline Placebo
22 Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis Completed NCT00001720 Phase 2 Alendronate
23 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
24 The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients Recruiting NCT03960554 Phase 2 Denosumab Inj 60 mg/ml
25 Prevention of Steroid-Induced Osteoporosis in Children Terminated NCT00022841 Phase 1, Phase 2 Pamidronate
26 Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol Unknown status NCT01974167 Eldecalcitol;Alfacalcidol
27 Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis Unknown status NCT02982083 Raloxifene hydrochloride;Placebo Oral Tablet
28 Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia Unknown status NCT01104324
29 Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication Completed NCT02472782 Teriparatide
30 Osteoporosis Prevention Among People With Rheumatoid Arthritis Receiving Oral Glucocorticoid Therapy Completed NCT00609830
31 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
32 Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids Recruiting NCT02719314 Glucocorticoid treatment
33 Glucocorticoids Promote Osteoclast Survival Terminated NCT00572299 alendronate

Search NIH Clinical Center for Glucocorticoid-Induced Osteoporosis

Genetic Tests for Glucocorticoid-Induced Osteoporosis

Anatomical Context for Glucocorticoid-Induced Osteoporosis

MalaCards organs/tissues related to Glucocorticoid-Induced Osteoporosis:

40
Bone, Kidney, Bone Marrow, Lung, Testes, Heart, Appendix

Publications for Glucocorticoid-Induced Osteoporosis

Articles related to Glucocorticoid-Induced Osteoporosis:

(show top 50) (show all 1207)
# Title Authors PMID Year
1
Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis. 61
32534995 2020
2
Extraction, purification and anti-osteoporotic activity of a polysaccharide from Epimedium brevicornum Maxim. in vitro. 61
31751710 2020
3
Pinocembrin alleviates glucocorticoid-induced apoptosis by activating autophagy via suppressing the PI3K/Akt/mTOR pathway in osteocytes. 61
32470335 2020
4
Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. 61
32377728 2020
5
Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis. 61
32224161 2020
6
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. 61
31628810 2020
7
Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. 61
32217159 2020
8
Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model. 61
32220570 2020
9
Effects of short- and long-term glucocorticoid-induced osteoporosis on plasma metabolome and lipidome of ovariectomized sheep. 61
32503480 2020
10
Bromodomain Protein BRD4 Accelerates Glucocorticoid Dysregulation of Bone Mass and Marrow Adiposis by Modulating H3K9 and Foxp1. 61
32575577 2020
11
History of risedronate. 61
32387834 2020
12
Glucocorticoids induce osteoporosis mediated by glucocorticoid receptor-dependent and -independent pathways. 61
32044718 2020
13
History of etidronate. 61
31911206 2020
14
In vitro and in vivo studies using non-traditional bisphosphonates. 61
32112989 2020
15
Glucocorticoid-induced autophagy and apoptosis in bone. 61
32157482 2020
16
Treatment options for glucocorticoid-induced osteoporosis. 61
32004105 2020
17
Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis. 61
31886921 2020
18
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. 61
32286516 2020
19
Views on glucocorticoid therapy in rheumatology: the age of convergence. 61
32076129 2020
20
Dexras1 plays a pivotal role in maintaining the equilibrium between adipogenesis and osteogenesis. 61
32335074 2020
21
Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway. 61
32253606 2020
22
Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). 61
32140784 2020
23
Tuna Bone Powder Alleviates Glucocorticoid-Induced Osteoporosis via Coregulation of the NF-κB and Wnt/β-Catenin Signaling Pathways and Modulation of Gut Microbiota Composition and Metabolism. 61
31953894 2020
24
Management of glucocorticoid-related osteoporotic vertebral fracture. 61
32226826 2020
25
Reduction of fibrillar strain-rate sensitivity in steroid-induced osteoporosis linked to changes in mineralized fibrillar nanostructure. 61
31726107 2020
26
Integrated metabolomic analysis for intervention effects of Gushudan on glucocorticoid-induced osteoporostic rat plasma based on RP/HILIC-UHPLC-Q-Orbitrap HRMS. 61
31874173 2020
27
A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England. 61
32054843 2020
28
Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression. 61
32079267 2020
29
The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. 61
32373775 2020
30
Icariin Alleviates Glucocorticoid-Induced Osteoporosis through EphB4/Ephrin-B2 Axis. 61
32508946 2020
31
A chitosan film containing quercetin-loaded transfersomes for treatment of secondary osteoporosis. 61
31942700 2020
32
Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. 61
31970477 2020
33
Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. 61
30877214 2020
34
Integrative Analysis for Elucidating Transcriptomics Landscapes of Glucocorticoid-Induced Osteoporosis. 61
32373610 2020
35
Off-label uses of denosumab in metabolic bone diseases. 61
31454537 2019
36
Ferulic acid, a natural polyphenol, protects against osteoporosis by activating SIRT1 and NF-κB in neonatal rats with glucocorticoid-induced osteoporosis. 61
31634777 2019
37
Extracellular vesicles from endothelial progenitor cells prevent steroid-induced osteoporosis by suppressing the ferroptotic pathway in mouse osteoblasts based on bioinformatics evidence. 61
31695092 2019
38
Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al. 61
31215777 2019
39
Where Does Denosumab Stand in the Treatment of Glucocorticoid-Induced Osteoporosis? Comment on the Article by Saag et al. 61
31216125 2019
40
High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. 61
31385078 2019
41
circRNA_0006393 promotes osteogenesis in glucocorticoid‑induced osteoporosis by sponging miR‑145‑5p and upregulating FOXO1. 61
31322188 2019
42
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. 61
30955181 2019
43
Management of glucocorticoid-induced osteoporosis: What is new? 61
31478605 2019
44
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. 61
30706148 2019
45
Hydrogen sulfide is a novel regulator implicated in glucocorticoids-inhibited bone formation. 61
31525733 2019
46
Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. 61
31053927 2019
47
Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. 61
31430857 2019
48
11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. 61
31420008 2019
49
3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopy. 61
30548522 2019
50
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. 61
30816640 2019

Variations for Glucocorticoid-Induced Osteoporosis

Expression for Glucocorticoid-Induced Osteoporosis

Search GEO for disease gene expression data for Glucocorticoid-Induced Osteoporosis.

Pathways for Glucocorticoid-Induced Osteoporosis

Pathways related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.31 SOST SFRP1 DKK1 AXIN2
2
Show member pathways
12.29 TNFSF11 TNFRSF11B FOS ACP5
3 12.09 SFRP1 PAX5 DKK1 AXIN2
4 11.91 TNFSF11 TNFRSF11B FOS CSF1 ACP5
5 11.74 RUNX2 PTH IGF1 BMP2 BGLAP
6 11.73 VDR TNFSF11 SOST RUNX2 PTH FOS
7 11.69 TNFSF11 PTH FOS CSF1 ACP5
8 11.62 VDR RUNX2 FOS
9 11.53 RUNX2 PTH IGF1
10 11.42 TNFSF11 IGF1 DKK1 CSF1
11 11.36 RUNX2 FOS BGLAP
12 11.02 VDR TNFSF11 RUNX2 PTH FOS BGLAP
13
Show member pathways
10.99 SOST SFRP1 DKK1
14 10.93 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
15 10.88 TNFSF11 IGF1 FOS CSF1 BMP2
16 10.86 TNFSF11 TNFRSF11B ACP5
17 10.8 CSF1 CD36
18 10.75 SFRP1 DKK1 BMP2
19 10.7 TNFSF11 TNFRSF11B PTH BGLAP
20 10.68 RUNX2 CSF1
21 10.55 VDR PTH

GO Terms for Glucocorticoid-Induced Osteoporosis

Cellular components related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNFSF11 TNFRSF11B SOST SFRP1 PTH IGF1
2 extracellular space GO:0005615 9.44 TNFSF11 TNFRSF11B SOST SFRP1 PTH MIR106B

Biological processes related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.19 VDR TNFSF11 SFRP1 PAX5 DKK1 BMP2
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.14 VDR PTH PAX5 DKK1 CD36 BMP2
3 negative regulation of transcription, DNA-templated GO:0045892 10.09 VDR SFRP1 RUNX2 CALCA BMP2
4 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 VDR TNFSF11 RUNX2 PTH PAX5 IGF1
5 positive regulation of transcription, DNA-templated GO:0045893 10.05 SOST SFRP1 RUNX2 IGF1 FOS BMP2
6 cytokine-mediated signaling pathway GO:0019221 9.99 TNFSF11 FOS CSF1 CD36
7 Wnt signaling pathway GO:0016055 9.96 SOST SFRP1 DKK1 AXIN2
8 response to drug GO:0042493 9.92 TNFRSF11B SFRP1 PTH FOS BGLAP
9 aging GO:0007568 9.91 PAX5 FOS CALCA BGLAP
10 cellular calcium ion homeostasis GO:0006874 9.87 VDR PTH CALCA
11 animal organ morphogenesis GO:0009887 9.86 VDR TNFSF11 PAX5 BMP2
12 cellular response to growth factor stimulus GO:0071363 9.83 SFRP1 BMP2 BGLAP
13 response to mechanical stimulus GO:0009612 9.81 SOST FOS BGLAP
14 positive regulation of osteoblast differentiation GO:0045669 9.8 RUNX2 IGF1 BMP2
15 negative regulation of gene expression GO:0010629 9.8 VDR SFRP1 MIR106B IGF1 CD36 BMP2
16 negative regulation of Wnt signaling pathway GO:0030178 9.79 SOST SFRP1 DKK1
17 positive regulation of cell death GO:0010942 9.77 DKK1 CD36 AXIN2
18 negative regulation of BMP signaling pathway GO:0030514 9.77 SOST SFRP1 DKK1
19 negative regulation of canonical Wnt signaling pathway GO:0090090 9.77 SOST SFRP1 DKK1 BMP2 AXIN2
20 cellular response to amyloid-beta GO:1904646 9.76 MIR106B IGF1 CD36
21 osteoblast differentiation GO:0001649 9.76 SFRP1 RUNX2 BMP2 BGLAP
22 positive regulation of gene expression GO:0010628 9.76 VDR TNFSF11 RUNX2 IGF1 DKK1 CSF1
23 bone mineralization GO:0030282 9.74 BMP2 BGLAP AXIN2
24 negative regulation of bone resorption GO:0045779 9.69 TNFRSF11B CALCA
25 positive regulation of ossification GO:0045778 9.69 PTH BMP2
26 cellular response to BMP stimulus GO:0071773 9.69 SFRP1 RUNX2 BMP2
27 negative regulation of peptidyl-tyrosine phosphorylation GO:0050732 9.68 SFRP1 MIR106B
28 regulation of osteoclast differentiation GO:0045670 9.68 TNFSF11 BGLAP
29 positive regulation of macrophage differentiation GO:0045651 9.68 CSF1 CALCA
30 cellular response to vitamin D GO:0071305 9.67 SFRP1 BGLAP
31 intestinal absorption GO:0050892 9.67 VDR CD36
32 regulation of ossification GO:0030278 9.67 RUNX2 CSF1
33 positive regulation of cell-matrix adhesion GO:0001954 9.67 SFRP1 CSF1 CD36
34 negative regulation of cardiac muscle cell differentiation GO:2000726 9.65 DKK1 BMP2
35 response to gravity GO:0009629 9.65 FOS BGLAP
36 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.64 RUNX2 BMP2
37 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.62 RUNX2 BMP2
38 bone mineralization involved in bone maturation GO:0035630 9.61 IGF1 BMP2
39 bone resorption GO:0045453 9.61 TNFSF11 PTH ACP5
40 positive regulation of osteoclast differentiation GO:0045672 9.58 TNFSF11 FOS CSF1
41 negative regulation of ossification GO:0030279 9.56 SOST SFRP1 DKK1 CALCA
42 Wnt signaling pathway involved in somitogenesis GO:0090244 9.55 SFRP1 DKK1
43 osteoclast proliferation GO:0002158 9.54 TNFSF11 CSF1
44 ossification GO:0001503 9.43 TNFSF11 SOST RUNX2 BMP2 BGLAP ACP5
45 skeletal system development GO:0001501 9.17 VDR TNFRSF11B RUNX2 PTH IGF1 BMP2

Molecular functions related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.63 VDR TSC22D3 RUNX2 PTH PAX5 FOS
2 co-receptor binding GO:0039706 9.26 DKK1 BMP2
3 cytokine activity GO:0005125 9.26 TNFSF11 TNFRSF11B CSF1 BMP2
4 growth factor activity GO:0008083 8.92 IGF1 DKK1 CSF1 BMP2

Sources for Glucocorticoid-Induced Osteoporosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....